XML 117 R45.htm IDEA: XBRL DOCUMENT v3.25.4
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Grant Contract Periods and Vesting Periods Options generally vest in accordance with the following schedule:
Shares vested by period
Contract Period6 MonthsYear 1Year 2Year 3
Directors
7 years100%—%—%—%
Employees
7 years—%—%50%50%
Schedule of Stock Compensation Activity
A summary of stock compensation activity for each of the three years ended December 31, 2025 is presented below:
202520242023
Stock-based compensation expense recognized(1)
$53,355 $40,118 $30,736 
Tax benefit recognized10,829 7,085 11,178 
(1)No stock-based compensation expense was capitalized in any period in accordance with applicable GAAP.
Schedule of Additional Information of Stock-Based Compensation
Additional stock compensation information is as follows at December 31:
20252024
Unrecognized compensation(1)
$49,461 $46,956 
Weighted average period of expected recognition (in years)(1)
0.640.53
(1)Includes stock options, restricted stock units and performance shares
Schedule of Options Outstanding
Options: The following table summarizes information about stock options outstanding at December 31, 2025.
 Options OutstandingOptions Exercisable
Range of
Exercise Prices		Number
Outstanding		Weighted-
Average
Remaining
Contractual
Life (Years)		Weighted-
Average
Exercise
Price		Number
Exercisable		Weighted-
Average
Exercise
Price
$50.64 - $98.32
1,283,918 1.89$92.51 1,283,918 $92.51 
100.74
745,000 1.15100.74 745,000 100.74 
103.23
935,490 3.14103.23 935,490 103.23 
105.56 - 128.40
1,339,536 4.97124.90 266,584 118.92 
$50.64 - $128.40
4,303,944 2.99$106.34 3,230,992 $99.69 
Schedule of Analysis of Option Activity
An analysis of option activity for each of the three years ended December 31, 2025, is as follows:
202520242023
OptionsWeighted-Average
Exercise Price		OptionsWeighted-Average
Exercise Price		OptionsWeighted-Average
Exercise Price
Outstanding—beginning of year
5,825,957 $99.74 5,940,320 $96.19 6,962,374 $91.73 
Granted:
7-year term
349,342 127.43 520,810 128.32 497,060 120.49 
Exercised(1,842,860)89.23 (584,993)88.52 (1,375,313)82.95 
Expired and forfeited(28,495)120.48 (50,180)106.62 (143,801)90.92 
Outstanding—end of year
4,303,944 $106.34 5,825,957 $99.74 5,940,320 $96.19 
Exercisable at end of year
3,230,992 $99.69 4,376,436 $93.73 4,003,028 $91.23 
Schedule of Additional Information on Unvested Options
Additional information about Globe Life's stock option activity as of December 31, 2025 and 2024 is as follows:
20252024
Outstanding options:
Weighted-average remaining contractual term (in years)2.993.15
Aggregate intrinsic value$144,251 $81,703 
Exercisable options:
Weighted-average remaining contractual term (in years)2.242.48
Aggregate intrinsic value$129,787 $77,946 

Selected stock option activity for the three years ended December 31, 2025, is presented below:
202520242023
Weighted-average grant-date fair value of options granted
(per share)		$39.92 $33.80 $32.25 
Intrinsic value of options exercised73,970 17,127 49,163 
Cash received from options exercised164,448 51,786 114,080 
Actual tax benefit received8,101 2,489 9,379 

Additional information concerning Globe Life's unvested options is as follows at December 31:
20252024
Number of shares outstanding1,072,952 1,449,521 
Weighted-average exercise price (per share)$126.38 $117.88 
Weighted-average remaining contractual term (in years)5.255.19
Aggregate intrinsic value$14,464 $3,757 
Schedule of Restricted Stock Units Outstanding And Vested
Following are the restricted stock units outstanding for each of the three years ended December 31, 2025:
Year of grantsOutstanding as of year end
2023163,108 
2024219,864 
2025(1)
312,663 
(1)Includes dividend equivalent units.
Schedule of Performance Shares Settled
Below is the final determination of the performance share grants in 2021 to 2023:
Year of grantsFinal settlement of sharesFinal settlement date
2021143,211 February 28, 2024
2022152,680 February 26, 2025
2023149,755 February 25, 2026
Schedule of Restricted Stock and Restricted Stock Units Granted
A summary of restricted stock grants for each of the years in the three-year period ended December 31, 2025, is presented in the table below:
2025(1)
20242023
Directors restricted stock:
Shares6,530 7,375 7,110 
Price per share$115.20 $122.06 $119.59 
Aggregate value$752 $900 $850 
Percent vested100%100%100%
Directors restricted stock units (including dividend equivalents):
Shares9,582 4,854 9,479 
Price per share$114.84 $120.16 $117.73 
Aggregate value$1,100 $583 $1,116 
Percent vested100%100%100%
Employees restricted stock units:
Shares106,089 101,011 96,975 
Price per share$127.43 $127.29 $120.18 
Aggregate value$13,519 $12,858 $11,654 
Percent vested—%—%—%
Performance shares:
Target shares148,688 96,800 81,300 
Target price per share$127.44 $128.40 $120.49 
Aggregate value$18,948 $12,429 $9,796 
Percent vested—%—%—%
(1)Includes dividend equivalent units.
Schedule of Analysis of Unvested Restricted Stock
An analysis of nonvested restricted stock is as follows:
Executive
Performance
Shares		Directors
Restricted
Stock		Directors
Restricted
Stock
Units
Employees
Restricted
Stock
Units
Total
2023:
Balance at December 31, 2022398,535 — — — 398,535 
Grants81,300 7,110 9,479 96,975 194,864 
Additional performance shares(1)
(28,857)— — — (28,857)
Restriction lapses(84,298)(7,110)(9,479)— (100,887)
Forfeitures(12,600)— — (4,410)(17,010)
Balance at December 31, 2023354,080 — — 92,565 446,645 
2024:
Grants96,800 7,375 4,854 101,011 210,040 
Additional performance shares(1)
84,712 — — — 84,712 
Restriction lapses(143,211)(7,375)(4,854)(437)(155,877)
Forfeitures(6,000)— — (10,008)(16,008)
Balance at December 31, 2024386,381 — — 183,131 569,512 
2025:
Grants148,688 6,530 9,582 106,089 270,889 
Additional performance shares(1)
83,626 — — — 83,626 
Restriction lapses(152,680)(6,530)(9,582)(2,473)(171,265)
Forfeitures— — — (20,399)(20,399)
Balance at December 31, 2025466,015 — — 266,348 732,363 
(1)Estimated additional (reduced) share grants expected due to achievement of performance criteria.
Schedule of Weighted-Average Grant-Date Fair Values of Unvested Restricted Stock
An analysis of the weighted-average grant-date fair values per share of non-vested restricted stock is as follows for the year 2025:
Executive Performance SharesDirectors Restricted StockDirectors Restricted Stock Units
Employees
Restricted
Stock
Units
Grant-date fair value per share at January 1, 2025
$115.78 $— $— $124.02 
Grants127.44 115.20 114.34 127.18 
Estimated additional performance shares126.75 — — — 
Restriction lapses(103.23)(115.20)(114.34)(119.99)
Forfeitures—— — (125.89)
Grant-date fair value per share at December 31, 2025
125.58 — — 125.17